CHRO (chromocell.com) Net Income

CHRO (Chromocell Therapeutics Corp.) - company brandmark

Chromocell Therapeutics (CHRO) is optimizing chemical supplies for the development of non-opioid analgesics, which is supported by the company's net position, currently valued at -0.01. Management is focusing on a narrow segment of chronic pain therapy through clinical trials. The business is currently in its early stages of development, utilizing raised capital to cover operating expenses in the absence of its own cash flow.

CHRO (Chromocell) Company Net Income history from 02/21/2024 to 07/02/2025

Analytical breakdowns and data insights for company Chromocell Therapeutics Corp. (CHRO)

- stock value and consensus price forecast:
Market Price Chromocell|CHRO - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Chromocell|CHRO - Enterprise Value
- company book value details:
Accounting Value of a Share Chromocell Therapeutics|CHRO - Company Book Value|Market Value to Book Value chromocell.com|CHRO - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Capital Chromocell Therapeutics|CHRO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Chromocell Therapeutics Corp|CHRO - Company Debts|Debts to Book Value Chromocell|CHRO - Company Long-Term Debts|Company Current Liabilities Chromocell Therapeutics|Immediate Liquidity chromocell.com
- net income and valuation multiples indicators:
CHRO - Company Net Income
Basic company analysis:CHRO Chromocell
Signature product of Chromocell Therapeutics Corporation

The selection of high-quality issuers is based on an analysis of free cash flows, where the final financial result determines the business's ability to generate value. This trend reflects real earnings, which for Chromocell Therapeutics (CHRO) directly depend on the patent monopolization of the pain therapy niche, allowing for the assessment of excess profit potential through the company's current profit levels.

Direct competitors

Company Net Income Biogen Idec (BIIB)|NBIX (Neurocrine Biosciences) - Net Profit|Net Income regencellbioscience.com (RGC)|Net Profit AXSM|ACAD (ACADIA Pharma) - Final Profit|Company Net Income Xenon Pharmaceuticals Inc XENE|Final Profit VKTX|SUPN - Company Net Income|Company Net Income catalystpharma.com|Denali Therapeutics Inc. (DNLI) - Company Net Income|Net Income Harmony Biosciences Inc|Company Net Income Biohaven Pharmaceutical|Company Net Income Amylyx Corp AMLX|Net Profit TRVI|Net Income praxismedicines.com PRAX|Net Profit AVXL (Anavex Life Sciences Corp.)|CeriBell Inc (CBLL) - Company Net Income|PRTA - Company Net Income|ALEC: Company Net Income|Annexon, Inc. (ANNX) - Company Net Income|OMER (Omeros) - Company Net Income|Net Income NGNE|ACIU: Final Profit|Net Income VYGR (Voyager Pharma)|Profit After Payment of Taxes NMRA|Net Profit SCLX (Scilex Holding Company)|Final Profit TVGN|Alpha Cognition Corp - Net Profit|Company Net Income cogrx.com|Inhibikase (IKT) - Company Net Income|Cassava Pharma - Final Profit|ASRT (Assertio Holdings) - Net Profit|Net Profit Coya|Company Net Income Vistagen Therapeutics (VTGN)|OVID: Profit After Tax|Net Profit ABOS (Acumen Pharma)|CervoMed Corporation (CRVO) - Company Net Income|ATHE: Net Income|CLNN - Net Profit|PEPG (pepgen.com) - Net Income|JUNS: Profit After Payment of Taxes|RLMD (Relmada) - Net Profit|Annovis Bio Corporation (ANVS) - Net Financial Result|Net Profit GRCE|Net Income fireflyneuro.com AIFF|Company Net Income Klotho Neurosciences KLTO|Net Financial Result NeuroSense Therapeutics Ltd (NRSN)|Reviva Pharmaceuticals Holdings - Net Profit|MetaVia Inc (MTVA) - Net Income|NRXS: Net Profit|Helius Medical Technologies - Final Profit|Company Net Income Passage Bio Inc.|NEUP: Final Profit|Company Net Income Minerva Neurosciences Corp (NERV)|ATHA - Company Net Income|Company Net Income Addex Therapeutics ADXN|ALZN: Company Profit|Cyclerion - Net Profit|Company Net Income Protagenic Therapeutics|KTTA (pasitheaclinics.com) - Net Income|Cortigent (CRGT) - Net Profit|Company Net Income Avenue Therapeutics|BCLI: Final Profit|Company Net Income Cara Therapeutics (CARA)|ELYM - Company Net Income|Net Profit ITCI (Intra-Cellular Therapies, Inc.)|LBPH - Net Income|Marinus Pharmaceuticals - Net Profit|Final Profit NKGN (nkgenbiotech.com)|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Sage Therapeutics Inc. - Final Profit|Company Net Income Neurotrope|Company Net Income Trevena Inc TRVN|Company Net Income Vigil Neuroscience (VIGL)|Net Income Anew Medical Inc. WENA|Company Net Income Cerevel Therapeutics, Inc. CERE